This suggests that structure is particularly sensitive to brain pathology and may represent a common source of functional deficit across conditions; however, to support this conclusion, further work should include AD biomarkers as PET with tau and/or amyloid tracers and quantitative measurements of cerebrospinal fluid tau and amyloid-beta species. This evidence concerns the gene MAPT and Alzheimer disease.